Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Biliary Cancer

 

SPI-1620w/ Docetaxel for Advanced Biliary Cancer
Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line Treatment for Patients With Advanced Biliary Cancer

Investigator: Gabriela Chiorean, MD;   Conditions: Biliary Cancer;    Status: Recruiting;   Study ID: NCT01773785